Jiangsu Nhwa Pharmaceutical Co., LTD
Simbol: 002262.SZ
SHZ
25.16
CNYTržna cena danes
23.9060
Razmerje P/E
2.4589
Razmerje PEG
25.35B
Kapaciteta MRK
- 0.00%
Donos DIV
Jiangsu Nhwa Pharmaceutical Co., LTD (002262-SZ) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 13635.22 | 3493.9 | 2984.2 | 2666 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 5823.3 | 1335 | 1452 | 1058.4 | |||||||||||||||||||
balance-sheet.row.net-receivables | 4452.03 | 1091.7 | 937.3 | 757.7 | |||||||||||||||||||
balance-sheet.row.inventory | 2592.65 | 628.6 | 716.3 | 604.3 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 94.68 | 40.3 | 12.6 | 15.1 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 20774.58 | 5254.6 | 4650.4 | 4043.2 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 5602.51 | 1539.5 | 1303.7 | 1158.3 | |||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 1083.69 | 276.2 | 223.8 | 167.5 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 1083.69 | 276.2 | 223.8 | 167.5 | |||||||||||||||||||
balance-sheet.row.long-term-investments | -1914.2 | 157.3 | -1333.4 | -928 | |||||||||||||||||||
balance-sheet.row.tax-assets | 218.31 | 58.3 | 37.5 | 30.7 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | 3137.07 | 42.3 | 1599.7 | 1225.5 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | 8127.38 | 2073.6 | 1831.3 | 1654 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 28901.96 | 7328.2 | 6481.7 | 5697.2 | |||||||||||||||||||
balance-sheet.row.account-payables | 1056.28 | 216.3 | 255.7 | 267.2 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 380.84 | 136.8 | 50.6 | 63 | |||||||||||||||||||
balance-sheet.row.tax-payables | 542.85 | 84.1 | 143.6 | 125.7 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 57.51 | 0.2 | 42.1 | 47.9 | |||||||||||||||||||
Deferred Revenue Non Current | 223.83 | 53.9 | 58 | 63.6 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 40.67 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 892.5 | 434.5 | 426.8 | 2.2 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 329.6 | 50.2 | 103 | 111.5 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 130.84 | 35.6 | 41.9 | 47.7 | |||||||||||||||||||
balance-sheet.row.total-liab | 3568.94 | 864.2 | 897 | 793.5 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.common-stock | 4030.35 | 1007.6 | 1007.6 | 1007.6 | |||||||||||||||||||
balance-sheet.row.retained-earnings | 18875.34 | 4813 | 3978.4 | 3366.1 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2478.66 | 611.2 | 617.6 | 528.3 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 21.03 | 2.3 | 18.7 | 18.7 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 25405.37 | 6434.1 | 5622.2 | 4920.7 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 28901.96 | 7328.2 | 6481.7 | 5697.2 | |||||||||||||||||||
balance-sheet.row.minority-interest | -126.22 | -24 | -37.5 | -17 | |||||||||||||||||||
balance-sheet.row.total-equity | 25279.15 | 6410.1 | 5584.8 | 4903.7 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 28901.96 | - | - | - | |||||||||||||||||||
Total Investments | 3909.1 | 1492.3 | 118.6 | 130.4 | |||||||||||||||||||
balance-sheet.row.total-debt | 512.6 | 172.6 | 92.8 | 110.9 | |||||||||||||||||||
balance-sheet.row.net-debt | -7299.32 | -1986.4 | -1439.4 | -1496.7 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 1074.77 | 1036.9 | 880.4 | 798 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 9.99 | 175.1 | 148.7 | 135.1 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -23.2 | -4 | 0.5 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -528.7 | 4 | 2.5 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | -144.64 | -178.6 | -160.6 | -251.1 | |||||||||||||||||||
cash-flows.row.account-receivables | -199.06 | -199.1 | -155.3 | -122.9 | |||||||||||||||||||
cash-flows.row.inventory | 54.43 | 54.4 | -128.2 | -205.9 | |||||||||||||||||||
cash-flows.row.account-payables | 0 | -33.9 | 126.9 | 77.1 | |||||||||||||||||||
cash-flows.row.other-working-capital | -0.01 | 0 | -4 | 0.5 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | -49.47 | 569 | -7.5 | 16.1 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 890.65 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -348.07 | -374 | -327.8 | -206.1 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 1.16 | 1.4 | 0.1 | 0.2 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | -6453.5 | -6453.5 | -5527.5 | 0.3 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 6518.29 | 6490.5 | 32.4 | 34.5 | |||||||||||||||||||
cash-flows.row.other-investing-activites | -313.73 | 0 | 5133.9 | -221.4 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -595.85 | -335.6 | -688.9 | -392.5 | |||||||||||||||||||
cash-flows.row.debt-repayment | -65 | -25 | -48 | -38 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0.5 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -0.5 | |||||||||||||||||||
cash-flows.row.dividends-paid | -206.97 | -201.5 | -202.7 | -102.3 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 15.5 | -1.1 | 10 | 12.9 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -215.97 | -210.2 | -240.8 | -127.4 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.53 | 0.4 | 0.9 | -1.1 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 105.47 | 626.7 | -67.7 | 180 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 7750.42 | 2158.9 | 1504.5 | 1572.2 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 7644.95 | 1532.2 | 1572.2 | 1392.2 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 890.65 | 1050.5 | 861 | 701.1 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -348.07 | -374 | -327.8 | -206.1 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 542.57 | 676.6 | 533.3 | 495 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 5182.87 | 4973.5 | 4298.5 | 3935.7 | |||||||||||||||||||
income-statement-row.row.cost-of-revenue | 1479.99 | 1460.4 | 1020.5 | 897.3 | |||||||||||||||||||
income-statement-row.row.gross-profit | 3702.89 | 3513.1 | 3278.1 | 3038.3 | |||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||
income-statement-row.row.research-development | 571.7 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-general-administrative | 48.23 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1753.34 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-expenses | -22.02 | -25.5 | 159 | 126.2 | |||||||||||||||||||
income-statement-row.row.operating-expenses | 2586.71 | 2443.5 | 2312.2 | 2116 | |||||||||||||||||||
income-statement-row.row.cost-and-expenses | 4066.7 | 3903.9 | 3332.7 | 3013.3 | |||||||||||||||||||
income-statement-row.row.interest-income | 19.62 | 23.8 | 25.5 | 17.7 | |||||||||||||||||||
income-statement-row.row.interest-expense | 4.89 | 4.2 | 4.9 | 5.1 | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1753.34 | - | - | - | |||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 64.73 | 89.4 | -13.6 | -10.1 | |||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-operating-expenses | -22.02 | -25.5 | 159 | 126.2 | |||||||||||||||||||
income-statement-row.row.total-operating-expenses | 64.73 | 89.4 | -13.6 | -10.1 | |||||||||||||||||||
income-statement-row.row.interest-expense | 4.89 | 4.2 | 4.9 | 5.1 | |||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 89.4 | 175.1 | 159.4 | 173.2 | |||||||||||||||||||
income-statement-row.row.ebitda-caps | 1239.16 | - | - | - | |||||||||||||||||||
income-statement-row.row.operating-income | 1136.69 | 1069.6 | 1003.5 | 925.9 | |||||||||||||||||||
income-statement-row.row.income-before-tax | 1201.43 | 1159 | 989.9 | 915.8 | |||||||||||||||||||
income-statement-row.row.income-tax-expense | 136.17 | 134.4 | 109.5 | 117.8 | |||||||||||||||||||
income-statement-row.row.net-income | 1074.77 | 1036.9 | 900.7 | 797.8 |
Pogosto zastavljeno vprašanje
Kaj je Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) skupna sredstva?
Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) skupna sredstva so 7328195368.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so 2705694560.000.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.714.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je 0.538.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je 0.207.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so 0.219.
Kaj je Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je 1036918058.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 172558561.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 2443472552.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 1635420861.000.